Skip to search formSkip to main contentSkip to account menu

JAK2 gene

Known as: Janus kinase 2, JTK10, Janus Kinase 2 (A Protein Tyrosine Kinase) Gene 
This gene is involved in erythropoiesis and signal transduction.
National Institutes of Health

Related topics

Related topics

22 relations
Cell Differentiation processCell ProliferationETV6 geneHodgkin Disease

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Ankylosing spondylitis: analysis of gene-gene interactions between IL-12β, JAK2, and STAT3 in Han Chinese and Algerian cohorts
Introduction Association studies have recently identified the importance of new genetic variants for ankylosing spondylitis (AS… 
Review
2018
Review
2018
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
2014
2014
Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models
The identification of JAK2 mutations in patients with myeloproliferative neoplasms (MPN) led to the clinical development of JAK2… 
2013
2013
JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients
Myeloproliferative neoplasms (MPNs) constitute a group of phenotypically diverse chronic myeloid malignancies, characterized by… 
2012
2012
Advantages of the quenching probe method over other PCR-based methods for detection of the JAK2 V617F mutation.
The detection of a V617F mutation (G to T exchange at nucleotide 1,849) in the JAK2 gene is crucial for the diagnosis of… 
2010
2010
JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
Background The JAK2 V617F mutation in exon 14 is the most common mutation in chronic myeloproliferative neoplasms (MPNs… 
2009
2009
[Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
BACKGROUND Real-time PCR for quantification of JAK2 V617F has recently been introduced and used to evaluate the importance of… 
2009
2009
Wild-Type JAK2 Secondary Acute Erythroleukemia Developing after JAK2-V617F-Mutated Primary Myelofibrosis
A 54-year-old female patient developed acute erythroleukemia after an 8-year course of primary myelofibrosis. The latter harbors… 
2008
2008
A new TMHA‐DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders
Refractory 
2008
2008
Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)